Revenue declined 19.5% year over year and fell 76.6% sequentially. Margins improved from the previous quarter, suggesting stronger cost discipline and operational efficiency. Year-over-year earnings remained under pressure, showing that the recovery in profitability is still incomplete.
Revenue pressure continues, indicating softer demand or pricing headwinds.
Margins improved from last quarter, suggesting that cost controls are starting to offset topline weakness.
The earnings story is shifting from pure growth toward efficiency, pricing discipline, and margin defense.
Revenue trend and year-over-year growth across recent reported quarterly periods.
Net income and net margin trend over recent reported quarterly periods.
Pfizer Inc. reported $14.9B in revenue for Q1 2024, down 19.5% YoY and down 76.6% QoQ. The year-over-year decline indicates ongoing pressure on topline performance.
Net income came in at $3.1B, down 43.7% YoY and up 193.3% QoQ. Net margin was 21%. Sequential margin improvement suggests stronger operating discipline despite a mixed revenue environment.
Quick factual answers for this report. Need the why behind them? Ask the report assistant.
Pfizer Inc. reported revenue of $14.9B in Q1 2024.
Pfizer Inc. reported net income of $3.1B in Q1 2024.
Pfizer Inc.'s revenue decreased by 19.5% year over year in Q1 2024.
Pfizer Inc.'s net margin was 21% in Q1 2024.
Compare this quarter with the previous earnings report.
Explore company profile, industry, and historical context.
View more quarterly financial trend pages for this company.
Financial data is sourced from company filings and internal processed earnings data.
YoY and QoQ values are derived from reported quarterly figures when not directly available.
This page is for informational purposes only and does not constitute investment advice.